NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Multiple Technology Appraisal (MTA)

Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed following prior chemotherapy (Review of TA162 and TA175)

Please sign and return to:

Nicola Cunliffe, Technology Appraisal Administrator
Email: TACommC@nice.org.uk
Fax: +44 (0)20 7061 9763
Post: NICE, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT

I confirm that:

- I agree with the content of the statement submitted by the Roy Castle Lung Cancer Foundation and consequently I will not be submitting a personal statement.

Name: JESME FOX

Signed: [redacted]

Date: 20/11/13